BLOOD 2022: CTX-1 Predicts Disease Progression Risk in Smoldering Myeloma Patients
Biomarker can differentiate progression types, identify risk from smoldering myeloma to multiple myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.